Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials

Abstract

Purpose: The purpose of this study was to identify patient characteristics that may be risk factors or markers of susceptibility to adverse treatment effects in cancer Phase I and II clinical trials.Patients and Methods: A total of 459 patients enrolled in 23 therapeutic Phase I and II studies at the Fox Chase Cancer Center were included in the analysis. Patient-specific characteristics, medical and treatment history, doses of experimental agents, and graded toxicities were extracted from case report forms. We developed a novel summary measure, the toxicity index (TI), to better discriminate patients on the basis of their overall toxicity experiences. Mixed model ANOVA was used to model TI on the basis of data from all trials using a specific agent. Generalized estimating equations in the context of binary logistic regression were used to model dose-limiting toxicity.Results: Seventeen pretreatment factors, including performance status, alkaline phosphatase, total bilirubin, serum creatinine, and tobacco use, emerged as significant predictors of toxicity as defined by dose-limiting toxicity or TI. Unexpectedly, dose was not always a predictor of toxicity. Even for values within the normal range, the TI identified serum bilirubin and alkaline phosphatase as predictors of toxicity after treatment with docetaxel and alkaline phosphatase as a predictor for toxicity after treatment with irinotecan.Conclusions: Independent of dose, certain pretreatment characteristics, including measures of organ function that are in the normal range, were found to be predictors of treatment toxicity. Because of its sensitivity to differences in overall toxicity, the TI should prove to be a useful tool for identifying predictors of chemotherapy-related toxicity.

Elderly Patients With Painful Bone Metastases Should be Offered Palliative Radiotherapy

“…Elderly cancer patients are a unique population in cancer care, because they are more likely to have metastatic disease and often have more symptoms than younger patients (2)(3)(4). Poor performance status and comorbidities, which are commonly experienced by elderly patients, have been related to negative treatment outcomes in chemotherapy for older adults (3)(4)(5)(6)(7)(8)(9)(10)(11). However, several studies have established chemotherapy as an effective treatment with minimal toxicity in elderly patients on the basis of age alone (4,8,(12)(13)(14).…”

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

“…Finally, our study has evaluated multiple molecularly targeted drugs in various tumor types, thus, our results cannot necessarily be applicable to all such agents in a specific way in view of the variety of these agents, their heterogeneous mechanisms of action, and adverse event profiles in different patient populations. Of note, another group examining the effects of patient characteristics on acute treatment toxicity in early phase clinical trials has used a similar methodology (23).…”

“…A modified toxicity index (TI) was calculated using the methods of Rogatko et al (23). Depending on the protocol, adverse events were graded on Consortium studies by the National Cancer Institute Common Toxicity Criteria versions 2.0 or 3.0.…”

New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

“…Our analysis of multiple phase I and early phase II trials revealed that dose is not always a significant predictor of toxicity (1). Even with conventional patient selection criteria that included the requirement for normal or near-normal hepatic and renal function, patient characteristics had greater predictive value than dose for the toxicity for several agents.…”